Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors

NCT ID: NCT00672269

Last Updated: 2009-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-04-30

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a high incidence among the first degree relatives of the carcinoid patients, indicating the involvement of genetic components in its initiation and pathogenesis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This proposed pilot study will conduct detailed interviews into the medical, environmental, and family histories and to collect blood specimen to obtain DNA. The Blood specimen and DNA will be processed by the Rutgers University Cell and DNA Repository (RUCDR) to rule out Familial Multiple Endocrine Neoplasia (MEN 1), and succinate dehydrogenase complex, subunit D (SDHD), gene inactivation thought to be associated with different types of carcinoid cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoid Neuroendocrine Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Families with carcinoid in multiple family members

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Over the age of 18 years
2. More than one ,member of a family with a history of biopsy confirmed carcinoid tumor
3. English speaking
4. Mentally and emotionally capable of answering questions
5. Willing and available for study participation
6. At least one other family member with carcinoid tumor

Exclusion Criteria

1. If you are under the age of 18 years,
2. If you are unable to understand or unable to provide informed consent,
3. If you have a psychological condition (i.e. depression, anxiety disorder, substance abuse, etc.) which might cause you significant problems in dealing with test results.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rutgers University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rutgers University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nancy Gardner, PhD

Role: PRINCIPAL_INVESTIGATOR

Rutgers University

Changshun Shao, PhD

Role: PRINCIPAL_INVESTIGATOR

Rutgers University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Busch Campus of Rutgers University, Human Genetics Institute

Piscataway, New Jersey, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nancy Gardner, PhD

Role: CONTACT

813-731-0894

Changshun Shao, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Changshun Shao, PhD

Role: primary

732-445-5406

Nancy Gardner, PhD

Role: backup

973-991-1302

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08-451

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cohort Study of Pancreatic Cancer Risk
NCT04247503 ACTIVE_NOT_RECRUITING